Jeffrey Lu

In January 2018, Jeffrey drove Engine Biosciences’ seed funding round of US$10m, one of the largest in Southeast Asia at the time. The biotech company uses advanced gene editing, data science and machine learning approaches to enable more efficient and effective discovery of therapies for cancers and neurodegenerative diseases. Jeffrey also serves as a board director of biotech startup Enleofen Bio, which is developing antibody therapeutics to treat fibrotic diseases.